Protagonist Therapeutics (PTGX) Assets Average (2016 - 2026)

Protagonist Therapeutics has disclosed Assets Average across 11 years of filings, most recently posting $682.8 million for Q1 2026.

• Assets Average for Q1 2026 came in at $682.8 million, down 8.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $682.8 million (down 8.15% YoY), and the FY2025 annual result was $706.5 million, up 28.13% from the prior year.
• Assets Average came in at $682.8 million for Q1 2026 at Protagonist Therapeutics, roughly flat from $684.9 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $743.4 million in Q1 2025 to a low of $243.9 million in Q1 2023.
• The 5-year median for Assets Average is $493.6 million (2024), against an average of $493.1 million.
• Across the five-year window, Assets Average dropped 29.91% in 2023 and soared 122.0% in 2024, its largest moves.
• Protagonist Therapeutics' Assets Average stood at $265.1 million in 2022, then grew by 29.78% to $344.0 million in 2023, then soared by 96.02% to $674.3 million in 2024, then increased by 1.58% to $684.9 million in 2025, then dropped by 0.31% to $682.8 million in 2026.
• The last three Assets Average figures came in at $682.8 million (Q1 2026), $684.9 million (Q4 2025), and $709.8 million (Q3 2025), per Business Quant data.